Liu et al. suggested that COX-2 inhibitors inhibited angiogenesis after chemotherapy, which was correlated with the inhibition of VEGF and platelet-derived factors.60 This may be a potential cause of the increased incidence of leukopenia and thrombocytopenia.61 Similarly, celecoxib combined with TKIs increased anemia, leukopenia, cardiovascular toxicity and other side effects. Here, PTGS2 is linked to anemia (phenotype).